↓ Skip to main content

Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?

Overview of attention for article published in British Journal of Pharmacology, October 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

patent
2 patents
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
95 Dimensions

Readers on

mendeley
88 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?
Published in
British Journal of Pharmacology, October 2015
DOI 10.1111/bph.13331
Pubmed ID
Authors

G O'Callaghan, A Houston

Abstract

Elevated expression of cyclooxygenase-2 (COX-2) and increased levels of prostaglandin E2 (PGE2 ) are found in numerous cancers, and are associated with tumour development and progression. Although epidemiological, clinical and pre-clinical studies have shown that the inhibition of PGE2 synthesis through the use of either non-steroidal anti-inflammatory drugs (NSAIDs) or specific COX-2 inhibitors (COXibs) has the potential to prevent and treat malignant disease; toxicities due to inhibition of COX-2 have limited their use. Thus, there is an urgent need for the development of strategies whereby COX-2 activity may be reduced without inducing any side effects. The biological effects of PGE2 are mediated by signalling through four distinct E-type prostanoid (EP) receptors -EP1, EP2, EP3 and EP4. In recent years, extensive effort has gone into elucidating the function of PGE2 and the EP receptors in health and disease, with the goal of creating selective inhibitors as a means of therapy. In this review, we focus on PGE2 , and in particular on the role of the individual EP receptors and their signalling pathways in neoplastic disease. As knowledge concerning the role of the EP receptors in cancer grows, so does the potential for exploiting the EP receptors as therapeutic targets for the treatment of cancer and metastatic disease.

Mendeley readers

The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 88 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 22 25%
Researcher 14 16%
Student > Master 14 16%
Student > Bachelor 9 10%
Professor > Associate Professor 4 5%
Other 12 14%
Unknown 13 15%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 22 25%
Agricultural and Biological Sciences 13 15%
Medicine and Dentistry 11 13%
Pharmacology, Toxicology and Pharmaceutical Science 10 11%
Immunology and Microbiology 8 9%
Other 8 9%
Unknown 16 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2021.
All research outputs
#2,754,146
of 19,562,105 outputs
Outputs from British Journal of Pharmacology
#715
of 6,934 outputs
Outputs of similar age
#67,037
of 378,380 outputs
Outputs of similar age from British Journal of Pharmacology
#9
of 25 outputs
Altmetric has tracked 19,562,105 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,934 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,380 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.